Description
Anti-PAI-1 Antibody, Non-Fucosylated (BioBet-1280ZP) is a human monoclonal IgG antibody against PAI-1. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
SLE; Scleroderma; Diabetic Nephropathy
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced PAI-1 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
SERPINE1
Full Name
serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1
Background
This gene encodes a member of the serine proteinase inhibitor (serpin) superfamily. This member is the principal inhibitor of tissue plasminogen activator (tPA) and urokinase (uPA), and hence is an inhibitor of fibrinolysis. Defects in this gene are the cause of plasminogen activator inhibitor-1 deficiency (PAI-1 deficiency), and high concentrations of the gene product are associated with thrombophilia. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.
Alternative Names
SERPINE1; serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1; PAI; PAI1; PAI-1; PLANH1; plasminogen activator inhibitor 1; serpin E1; endothelial plasminogen activator inhibitor; serine (or cysteine) proteinase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1
Gene ID
5054
Cellular Localization
Extracellular region or secreted
Involvement in Disease
Diseases associated with SERPINE1 include Plasminogen Activator Inhibitor-1 Deficiency and Hepatic Veno-Occlusive Disease.
Related Pathways
Its related pathways are Transcriptional activity of SMAD2/SMAD3-SMAD4 heterotrimer and E2F transcription factor network.
Function
Serine protease inhibitor. Inhibit TMPRSS7. It is the main inhibitor of tissue-type plasminogen activator (PLAT) and urokinase-type plasminogen activator (PLAU). As a PLAT inhibitor, it is necessary for down-regulation of fibrinolytic protein and is responsible for controlling the degradation of thrombus. As a PLAU inhibitor, it participates in the regulation of cell adhesion and proliferation. As a regulator of cell migration, it is independent of protease inhibitors. It is necessary to stimulate the migration of keratinocytes during the repair of skin damage. It is involved in cell and replication senescence. Plays a role in aging of lung alveolar type 2 cells (similar). Participate in the regulation of the cementoblast differentiation of periodontal ligament stem cells, and regulate the dentin differentiation and dentin formation in the process of dentin formation.
Field of research
Cancer antibody; Cell Biology and Cellular Response antibody; Metabolism antibody
Post-translational modifications
Inactivated by proteolytic attack of the urokinase-type (u-PA) and the tissue-type (TPA), cleaving the 369-Arg-|-Met-370 bond.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
BioBet-1280ZP
Description
The antibody molecules which bind plasminogen activator inhibitor 1 (PAI-1) are useful for treating diseases and conditions caused or exacerbated by fibrosis, such as systemic lupus erythromatosus (SLE), scleroderma, pulmonary fibrosis (wherein the disease is not idiopathic pulmonary fibrosis (IPF)), diabetic nephropathy, lupus nephritis, graft versus host disease, glomerulonephritis, focal segmental glomerulosclerosis, membranous nephropathy, mesangial proliferative glomerulonephritis, membranoproliferative glomerulonephritis, renal fibrosis, and COPD.
Antibody Indication
SLE; Scleroderma; Diabetic Nephropathy
SLE; Scleroderma; Diabetic Nephropathy
